Luvixasertib monotherapy and with fulvestrant in advanced solid tumors and breast cancer

Phase 2, open-label trial of luvixasertib in solid tumor (advanced stage) and breast cancer (2 arms), sponsored by Treadwell Therapeutics. Primary endpoints: Incidence of adverse events of CFI-402257 as a single agent and at the recommended phase 2 dose (RP2D) at 48 months and Incidence of adverse events of CFI-402257 in combination with fulvestrant and at the recommended phase 2 dose (RP2D) at 48 months. Started May 2022; status: active, not recruiting.